Printer Friendly
The Free Library
22,728,043 articles and books

Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting.



First in a Series of Novel [eth]-Amyloid Imaging Compounds from the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli.

http://upenn.edu/.

Address: Philadelphia, PA, USA.
 

PHILADELPHIA -- Avid Radiopharmaceuticals, Inc. (Avid), a product-focused molecular imaging company, today announced the presentation of the first results from a clinical study of 18F-AV-1/ZK (AV-1), a novel radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes.  for positron emission tomography positron emission tomography: see PET scan.
positron emission tomography (PET)

Imaging technique used in diagnosis and biomedical research.
 (PET) imaging of amyloid plaques in patients with Alzheimer's disease. Principal investigator Dr. Christopher Rowe from Austin Hospital of Melbourne, a leading investigator in the field of molecular imaging of Alzheimer's disease, presented the results at the 8th International Conference on AD/PD in Salzburg, Austria.

The goal of this first clinical study was to examine whether PET imaging with AV-1 could be used to distinguish patients with Alzheimer's disease from those with normal cognitive function. AV-1 binds avidly to [eth]-amyloid, the chief constituent of amyloid plaques, which accumulates abnormally in the brains of people with Alzheimer's disease.

Dr. Rowe reported that PET imaging with AV-1 clearly distinguishes AD from healthy elderly subjects, and may be used to quantify amyloid amyloid /am·y·loid/ (am´i-loid)
1. starchlike; amylaceous.

2. the pathologic, extracellular, waxy, amorphous substance deposited in amyloidosis, being composed of fibrils in bundles or in a meshwork of polypeptide
 burden. AV-1 PET scans showed high levels of signal in the Alzheimer's patients, particularly in areas of the brain known to contain amyloid plaques. In contrast there was no retention of AV-1 in the cerebellar cortex, an area where amyloid plaques do not accumulate.

This is the first scientific report of a clinical trial with an 18F-compound designed for specifically imaging amyloid plaques in AD. The wide availability of 18F allows for the possibility of amyloid imaging at a large number of clinical sites worldwide.

"We are extremely encouraged by the results of this clinical study with Avid's first compound, AV-1. These data have provided the rationale for Avid's next generation compounds for amyloid imaging, which are now in clinical trials in the United States," said Daniel Skovronsky, MD, PhD, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Avid.

AV-1 is one of a series of novel compounds discovered in the laboratory of Dr. Hank Kung from the University of Pennsylvania and exclusively licensed to Avid for development and commercialization. The results presented represent a collaborative effort between scientists at Austin Health, the University of Melbourne
  • AsiaWeek is now discontinued.
Comments:

In 2006, Times Higher Education Supplement ranked the University of Melbourne 22nd in the world. Because of the drop in ranking, University of Melbourne is currently behind four Asian universities - Beijing University,
, Neuroscience Victoria, Avid Radiopharmaceuticals, the University of Pennsylvania, and Bayer Schering Pharma.

New treatment methods for slowing or reversing the deposition of insoluble amyloid in the brains of people with Alzheimer's disease are the subject of intensive clinical research by many large pharmaceutical companies as well as the National Institute of Mental Health The National Institute of Mental Health (NIMH) is part of the federal government of the United States and the largest research organization in the world specializing in mental illness.  (NIMH) (www.nimh.nih.gov/studies/1alzhdis.cfm). Amyloid imaging may help in identifying those patients who will benefit from these emerging treatments.

About Avid

Avid Radiopharmaceuticals, Inc. is developing novel diagnostic imaging agents to enable the early diagnosis, treatment selection and therapeutic monitoring of major medical disorders. The company is a pioneer in the development of molecular imaging agents for Alzheimer's disease. Its lead product candidates are being developed to identify amyloid plaques, which are thought to accumulate in the brain for years before the onset of clinical symptoms of the disease. Avid's compounds may enable the earlier diagnosis of Alzheimer's disease and also allow researchers to better evaluate therapeutic drug candidates for the prevention or reversal of amyloid plaque build-up in the brain. Avid's technology can be used with a variety of imaging technologies such as positron emission tomography (PET) and single photon computed tomography (SPECT SPECT single-photon emission computed tomography.

SPECT
abbr.
single photon emission computed tomography


SPECT,
n See single photon emission computer tomography.
) and is currently being tested in a number of pilot human studies. In July 2006 Bayer Schering Pharma AG Bayer Schering Pharma AG (FWB: SCH, NYSE: SHR) is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on December 29 2006. The company was originally founded in 1851 by Ernst Schering (1824-1889). , Germany, a worldwide leader in specialized pharmaceuticals, and Avid announced a collaboration they have formed through which Bayer Schering Pharma has an exclusive option to develop and market certain of the Avid PET molecular imaging agents known as 18F-stilbenes for Alzheimer's disease. Avid, in collaboration with Dr. Hank Kung of the University of Pennsylvania, also continues its research and development of other new [eth]-amyloid molecular imaging agents; two of which have now entered IND studies. Avid has also initiated an IND study of a new 18F-PET compound for imaging the vesicular monoamine transporter The vesicular monoamine transporter is a transport protein located within the presynaptic cell. It comprises the two isoforms:
  • VMAT1
  • VMAT2
Further reading
  • Kilbourn MR (1997).
 (VMAT-2) which is implicated im·pli·cate  
tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates
1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot.

2.
 in diseases involving dopaminergic dopaminergic /do·pa·min·er·gic/ (do?pah-men-er´jik) activated or transmitted by dopamine; pertaining to tissues or organs affected by dopamine.

do·pa·mi·ner·gic
adj.
 degeneration such as Parkinson's disease (PD) and Dementia with Lewy Bodies Dementia with Lewy bodies is the second most frequent cause of hospitalization for dementia, after Alzheimer's disease. Current estimates are that about 60-to-75% of diagnosed dementias are of the Alzheimer's and mixed (Alzheimer's and vascular dementia) type, 10-to-15% are Lewy  (DLB DLB Dementia with Lewy Bodies
DLB Dynamic Load Balancing
DLB Don't Look Back
DLB Digital Lecture Board (University of Mannheim, Germany)
DLB Digital Loopback
DLB Downline Builder (multi-level marketing) 
). The VMAT-2 imaging program has grown out of a close collaboration with the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries.  as well as the University of Pennsylvania. Avid has also begun a research program on imaging [eth]- cells of the pancreas, as a marker of the onset and progression of diabetes mellitus. For more information, visit www.avidrp.com.

About Alzheimer's Disease

According to the Alzheimer's Association (www.alz.org) there are an estimated 4.5 million people in the United States alone who have Alzheimer's disease. The number of people with Alzheimer's disease is expected to grow - by 2050 the number of individuals with Alzheimer's could range from 11.3 million to 16 million. People with Alzheimer's disease typically experience a progression of symptoms resulting from the underlying nerve cell degeneration that takes place in Alzheimer's disease. Nerve cell damage typically begins with cells involved in learning and memory and later extends to cells that control every aspect of thinking, judgment, and behavior. According to a report commissioned by the Alzheimer's Association (www.alz.org/AboutAD/statistics.asp), Alzheimer's disease costs American businesses $61 billion a year. Of that figure, $24.6 billion covers Alzheimer's health care and $36.5 billion covers costs related to caregivers of individuals with Alzheimer's disease, including lost productivity, absenteeism and worker replacement. Medicare costs for beneficiaries with Alzheimer's are expected to increase 75 percent, from $91 billion in 2005 to $160 billion in 2010 and Medicaid expenditures on residential dementia care are expected to increase from $21 billion in 2005 to $24 billion in 2010.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Clinical report
Date:Mar 19, 2007
Words:941
Previous Article:Blue Sky Network Partners with Nigerian Reseller to Expand Business in West Africa.
Next Article:Fitch Affirms Burlington Coat Factory's IDR at 'B-'; Upgrades Sr Notes to 'CCC+/RR5'.
Topics:



Related Articles
Highlights From the Annual Scientific Assembly: Managing the Stages of Alzheimer's Disease--new management options. (Special Feature).
Toward a new understanding of aging.
Early environmental origins of neurodegenerative disease in later life.
Neurodegenerative diseases: an overview of environmental risk factors.
Two New Drugs for the Treatment of Alzheimer's Disease are Expected to Enter the Market by 2008.
The Sale Of Alzheimer's Disease (AD) And Parkinson's Disease (PD) Medication Varies Between Each Country, For Example 55% Of AD Drug Sales Are...
Siemens and UCLA Researchers Get FDA "Green Light" for Clinical Study of Alzheimer's-Specific Imaging Agent.
DiaGenic ASA Presents Prototypes of the First Early Bloodtest for Alzheimer's Disease at AD/PD 2007.
Avid Radiopharmaceuticals Closes $26 Million Series C Financing.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters